Dosage and administration
Nonvalvular atrial fibrillation
CrCl | Dose |
---|---|
>95 mL/min | DO NOT USE! |
>50 to ≤95 mL/min | 60 mg PO once daily |
≥15 to <50 mL/min | 30 mg PO once daily |
<15 mL/min | DO NOT USE! |
Note: Do not use with CrCl >95 mL/min!
DVT and PE
CrCl | Dose |
---|---|
>50 mL/min | 60 mg orally once daily |
≥15 to <50 mL/min | 30 mg orally once daily |
Patients with body weight ≤60 kg or receiving certain P-gp inhibitors (verapamil, quinidine, azithromycin, clarithromycin, erythromycin, itraconazole or ketoconazole) use 30 mg once daily.
Dosage forms and strengths
- Tablets
- 15 mg
- 30 mg
- 60 mg
Contraindications
- Active pathological bleeding
Warnings and precautions
- Bleeding: serious and potentially fatal bleeding. Promptly evaluate signs and symptoms of blood loss.
- Mechanical heart valves or moderate to severe mitral stenosis: Use is not recommended.
Adverse reactions
- Treatment of nonvalvular AF: The most common adverse reactions (≥5%) are bleeding and anemia.
- Treatment of DVT and PE: The most common adverse reactions (≥1%) are bleeding, rash, abnormal liver function tests and anemia.
Drug interactions
- Anticoagulants: Avoid concomitant use.
- Rifampin: Avoid concomitant use.
Use in specific populations
- Nursing mothers: Discontinue drug or discontinue nursing.
- Impaired renal function: Reduce dose (see tables above).
- Moderate or severe hepatic impairment: Not recommended.